DRUG-CLASS OVERVIEW:@0.982174:0.513429:0.982174:0.311367:0.954164:0.311367:0.954164:0.513429:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.233372:0.041064:0.000000:0.000000:0.019473
183:@0.945393:0.038601:0.984904:0.038601:0.984904:0.019004:0.945393:0.019004:0.013170:0.013170:0.013170
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
as  well  as  gastro-oesophageal  cancer, :@0.084848:0.079499:0.481078:0.079499:0.481078:0.063743:0.084848:0.063743:0.012758:0.007081:0.005330:0.010670:0.015606:0.012123:0.003464:0.003464:0.005330:0.010670:0.012758:0.007081:0.005330:0.010670:0.012565:0.012758:0.007081:0.006138:0.005328:0.012219:0.006004:0.012219:0.012123:0.007081:0.012219:0.012738:0.011353:0.012758:0.012565:0.012123:0.012758:0.003464:0.005330:0.010670:0.012065:0.012758:0.011353:0.012065:0.012123:0.003383:0.005326:0.005330
prostate cancer, bladder cancer, cervical :@0.084848:0.095017:0.481121:0.095017:0.481121:0.079261:0.084848:0.079261:0.012738:0.005328:0.012219:0.007081:0.006138:0.012758:0.006138:0.012123:0.008736:0.012065:0.012758:0.011353:0.012065:0.012123:0.003383:0.004945:0.008736:0.012738:0.003464:0.012758:0.012796:0.012796:0.012123:0.005407:0.008736:0.012065:0.012758:0.011353:0.012065:0.012123:0.003383:0.004945:0.008736:0.012065:0.012123:0.005407:0.010275:0.003464:0.012065:0.012758:0.003852:0.005330
cancer and head and neck cancer.:@0.084848:0.110535:0.440207:0.110535:0.440207:0.094779:0.084848:0.094779:0.012065:0.012758:0.011353:0.012065:0.012123:0.005407:0.010449:0.012758:0.011353:0.012796:0.010449:0.011353:0.012123:0.012758:0.012796:0.010449:0.012758:0.011353:0.012796:0.010449:0.011353:0.012123:0.012065:0.009275:0.010449:0.012065:0.012758:0.011353:0.012065:0.012123:0.003993:0.005330
4,13,99:@0.439806:0.104917:0.475749:0.104917:0.475749:0.095732:0.439806:0.095732:0.005991:0.002883:0.005991:0.005991:0.002883:0.005991:0.006215
 :@0.475757:0.110536:0.481087:0.110536:0.481087:0.094780:0.475757:0.094780:0.005330
Docetaxal has similar therapeutic and toxic :@0.084848:0.126054:0.481087:0.126054:0.481087:0.110298:0.084848:0.110298:0.013932:0.012219:0.012065:0.012123:0.006138:0.012758:0.008852:0.012758:0.003464:0.005292:0.011353:0.012758:0.007081:0.005292:0.007081:0.003464:0.017665:0.003464:0.003464:0.012758:0.005407:0.005292:0.006138:0.011353:0.012123:0.005407:0.012758:0.012738:0.012123:0.011315:0.006138:0.003464:0.012065:0.005292:0.012758:0.011353:0.012796:0.005292:0.006138:0.012219:0.008852:0.003464:0.012450:0.005330
properties as etoposide and is indicated as :@0.084848:0.141572:0.481051:0.141572:0.481051:0.125816:0.084848:0.125816:0.012738:0.005328:0.012219:0.012738:0.012123:0.005407:0.006138:0.003464:0.012123:0.007081:0.006023:0.012758:0.007081:0.006023:0.012123:0.006138:0.012219:0.012738:0.012219:0.007081:0.003464:0.012796:0.012123:0.006023:0.012758:0.011353:0.012796:0.006023:0.003464:0.007081:0.006023:0.003464:0.011353:0.012796:0.003464:0.012065:0.012758:0.006138:0.012123:0.012796:0.006023:0.012758:0.007470:0.005330
adjuvant treatment of patients with oper :@0.084848:0.157090:0.481137:0.157090:0.481137:0.141334:0.084848:0.141334:0.012758:0.012796:0.003521:0.011315:0.010275:0.012758:0.011353:0.006138:0.010237:0.006138:0.005326:0.012123:0.012758:0.006138:0.017665:0.012123:0.011353:0.006138:0.010237:0.012219:0.005657:0.010237:0.012738:0.012758:0.006138:0.003464:0.012123:0.011353:0.006138:0.007081:0.010237:0.015606:0.003464:0.006138:0.011353:0.010237:0.012219:0.012738:0.012123:0.005788:0.005330
node-positive breast cancer in combination :@0.084848:0.172608:0.481091:0.172608:0.481091:0.156852:0.084848:0.156852:0.011353:0.012219:0.012796:0.012123:0.006004:0.012738:0.012219:0.007081:0.003464:0.006138:0.003464:0.010275:0.012123:0.004085:0.012738:0.005328:0.012123:0.012758:0.007081:0.006138:0.004087:0.012065:0.012758:0.011353:0.012065:0.012123:0.005407:0.004085:0.003464:0.011353:0.004087:0.012065:0.012219:0.017665:0.012738:0.003464:0.011353:0.012758:0.006138:0.003464:0.012219:0.011736:0.005330
with doxorubicin and cyclophosphamide, :@0.084848:0.188125:0.481085:0.188125:0.481085:0.172369:0.084848:0.172369:0.015606:0.003464:0.006138:0.011353:0.010064:0.012796:0.012219:0.008852:0.012219:0.005407:0.011315:0.012738:0.003464:0.012065:0.003464:0.011353:0.010064:0.012758:0.011353:0.012796:0.010064:0.012065:0.009929:0.012065:0.003464:0.012219:0.012738:0.011353:0.012219:0.007081:0.012738:0.011353:0.012758:0.017665:0.003464:0.012796:0.012123:0.005328:0.005330
locally advanced metastatic breast cancer :@0.084848:0.203643:0.481070:0.203643:0.481070:0.187887:0.084848:0.187887:0.003464:0.012219:0.012065:0.012758:0.003464:0.003464:0.009929:0.004491:0.012758:0.012796:0.010275:0.012758:0.011353:0.012065:0.012123:0.012796:0.004489:0.017665:0.012123:0.006138:0.012758:0.007081:0.006138:0.012758:0.006138:0.003464:0.012065:0.004489:0.012738:0.005328:0.012123:0.012758:0.007081:0.006138:0.004491:0.012065:0.012758:0.011353:0.012065:0.012123:0.005788:0.005330
in combination with doxorubicin in patients :@0.084848:0.219161:0.481095:0.219161:0.481095:0.203405:0.084848:0.203405:0.003464:0.011353:0.006242:0.012065:0.012219:0.017665:0.012738:0.003464:0.011353:0.012758:0.006138:0.003464:0.012219:0.011353:0.006242:0.015606:0.003464:0.006138:0.011353:0.006244:0.012796:0.012219:0.008852:0.012219:0.005407:0.011315:0.012738:0.003464:0.012065:0.003464:0.011353:0.006244:0.003464:0.011353:0.006242:0.012738:0.012758:0.006138:0.003464:0.012123:0.011353:0.006138:0.007470:0.005330
who  have  not  received  cytotoxic  therapy :@0.084848:0.234679:0.481110:0.234679:0.481110:0.218923:0.084848:0.218923:0.015606:0.011353:0.012219:0.005330:0.002934:0.011353:0.012758:0.010275:0.012123:0.005330:0.002933:0.011353:0.012219:0.006138:0.005330:0.002933:0.005328:0.012123:0.012065:0.012123:0.003464:0.010275:0.012123:0.012796:0.005330:0.002933:0.012065:0.009929:0.006138:0.012219:0.006138:0.012219:0.008852:0.003464:0.012065:0.005330:0.002934:0.006138:0.011353:0.012123:0.005407:0.012758:0.012738:0.010316:0.005330
for this condition, locally advanced or met-:@0.084848:0.250197:0.475738:0.250197:0.475738:0.234441:0.084848:0.234441:0.005657:0.012219:0.005407:0.005888:0.006138:0.011353:0.003464:0.007081:0.005888:0.012065:0.012219:0.011353:0.012796:0.003464:0.006138:0.003464:0.012219:0.011353:0.004945:0.005888:0.003464:0.012219:0.012065:0.012758:0.003464:0.003464:0.009929:0.005888:0.012758:0.012796:0.010275:0.012758:0.011353:0.012065:0.012123:0.012796:0.005888:0.012219:0.005407:0.005888:0.017665:0.012123:0.006138:0.006388
astatic breast cancer after failure of cyto-:@0.084848:0.265714:0.475792:0.265714:0.475792:0.249958:0.084848:0.249958:0.012758:0.007081:0.006138:0.012758:0.006138:0.003464:0.012065:0.007966:0.012738:0.005328:0.012123:0.012758:0.007081:0.006138:0.007966:0.012065:0.012758:0.011353:0.012065:0.012123:0.005407:0.007966:0.012758:0.005657:0.006138:0.012123:0.005407:0.007966:0.005657:0.012758:0.003464:0.003464:0.011315:0.005328:0.012123:0.007966:0.012219:0.005657:0.007966:0.012065:0.009929:0.006138:0.012219:0.006388
toxic therapy, locally advanced or meta-:@0.084848:0.281232:0.475757:0.281232:0.475757:0.265476:0.084848:0.265476:0.006138:0.012219:0.008852:0.003464:0.012065:0.009159:0.006138:0.011353:0.012123:0.005407:0.012758:0.012738:0.009929:0.004945:0.009159:0.003464:0.012219:0.012065:0.012758:0.003464:0.003464:0.009929:0.009159:0.012758:0.012796:0.010275:0.012758:0.011353:0.012065:0.012123:0.012796:0.009159:0.012219:0.005407:0.009159:0.017665:0.012123:0.006138:0.012758:0.006388
static breast cancer in combination with :@0.084848:0.296750:0.481120:0.296750:0.481120:0.280994:0.084848:0.280994:0.007081:0.006138:0.012758:0.006138:0.003464:0.012065:0.010833:0.012738:0.005328:0.012123:0.012758:0.007081:0.006138:0.010833:0.012065:0.012758:0.011353:0.012065:0.012123:0.005407:0.010833:0.003464:0.011353:0.010833:0.012065:0.012219:0.017665:0.012738:0.003464:0.011353:0.012758:0.006138:0.003464:0.012219:0.011353:0.010833:0.015606:0.003464:0.006138:0.011734:0.005330
capecitabine after failure of cytotoxic :@0.084848:0.312268:0.481085:0.312268:0.481085:0.296512:0.084848:0.296512:0.012065:0.012758:0.012738:0.012123:0.012065:0.003464:0.006138:0.012758:0.012738:0.003464:0.011353:0.012123:0.017395:0.012758:0.005657:0.006138:0.012123:0.005407:0.017395:0.005657:0.012758:0.003464:0.003464:0.011315:0.005328:0.012123:0.017395:0.012219:0.005657:0.017395:0.012065:0.009929:0.006138:0.012219:0.006138:0.012219:0.008852:0.003464:0.012450:0.005330
chemotherapy where previous therapy did :@0.084848:0.327786:0.481103:0.327786:0.481103:0.312030:0.084848:0.312030:0.012065:0.011353:0.012123:0.017665:0.012219:0.006138:0.011353:0.012123:0.005407:0.012758:0.012738:0.009929:0.006023:0.015606:0.011353:0.012123:0.005328:0.012123:0.006023:0.012738:0.005328:0.012123:0.010275:0.003464:0.012219:0.011315:0.007081:0.006023:0.006138:0.011353:0.012123:0.005407:0.012758:0.012738:0.009929:0.006023:0.012796:0.003464:0.013181:0.005330
not include an anthracycline, in combina-:@0.084848:0.343303:0.475796:0.343303:0.475796:0.327548:0.084848:0.327548:0.011353:0.012219:0.006138:0.007582:0.003464:0.011353:0.012065:0.003464:0.011315:0.012796:0.012123:0.007582:0.012758:0.011353:0.007582:0.012758:0.011353:0.006138:0.011353:0.005407:0.012758:0.012065:0.009929:0.012065:0.003464:0.003464:0.011353:0.012123:0.004945:0.007582:0.003464:0.011353:0.007582:0.012065:0.012219:0.017665:0.012738:0.003464:0.011353:0.012758:0.006388
tion with cisplatin for unresected locally ad-:@0.084848:0.358821:0.475736:0.358821:0.475736:0.343065:0.084848:0.343065:0.006138:0.003464:0.012219:0.011353:0.005600:0.015606:0.003464:0.006138:0.011353:0.005600:0.012065:0.003464:0.007081:0.012738:0.003464:0.012758:0.006138:0.003464:0.011353:0.005600:0.005657:0.012219:0.005407:0.005600:0.011315:0.011353:0.005328:0.012123:0.007081:0.012123:0.012065:0.006138:0.012123:0.012796:0.005600:0.003464:0.012219:0.012065:0.012758:0.003464:0.003464:0.009929:0.005600:0.012758:0.012796:0.006388
vanced or metastatic non-small-cell lung :@0.084848:0.374339:0.481083:0.374339:0.481083:0.358583:0.084848:0.358583:0.010275:0.012758:0.011353:0.012065:0.012123:0.012796:0.011007:0.012219:0.005407:0.011007:0.017665:0.012123:0.006138:0.012758:0.007081:0.006138:0.012758:0.006138:0.003464:0.012065:0.011007:0.011353:0.012219:0.011353:0.006004:0.007081:0.017665:0.012758:0.003464:0.003464:0.006004:0.012065:0.012123:0.003464:0.003464:0.011007:0.003464:0.011315:0.011353:0.012946:0.005330
cancer where chemotherapy has not previ-:@0.084848:0.389857:0.475790:0.389857:0.475790:0.374101:0.084848:0.374101:0.012065:0.012758:0.011353:0.012065:0.012123:0.005407:0.004310:0.015606:0.011353:0.012123:0.005326:0.012123:0.004310:0.012065:0.011353:0.012123:0.017665:0.012219:0.006138:0.011353:0.012123:0.005407:0.012758:0.012738:0.009929:0.004310:0.011353:0.012758:0.007081:0.004310:0.011353:0.012219:0.006138:0.004310:0.012738:0.005328:0.012123:0.010275:0.003464:0.006388
ously been administered for this condition, :@0.084848:0.405375:0.481097:0.405375:0.481097:0.389619:0.084848:0.389619:0.012219:0.011315:0.007081:0.003464:0.009929:0.007955:0.012738:0.012123:0.012123:0.011353:0.007953:0.012758:0.012796:0.017665:0.003464:0.011353:0.003464:0.007081:0.006138:0.012123:0.005328:0.012123:0.012796:0.007953:0.005657:0.012219:0.005407:0.007953:0.006138:0.011353:0.003464:0.007081:0.007955:0.012065:0.012219:0.011353:0.012796:0.003464:0.006138:0.003464:0.012219:0.011353:0.005328:0.005330
locally advanced or metastatic non-small-:@0.084848:0.420893:0.475757:0.420893:0.475757:0.405137:0.084848:0.405137:0.003464:0.012219:0.012065:0.012758:0.003464:0.003464:0.009929:0.007735:0.012758:0.012796:0.010275:0.012758:0.011353:0.012065:0.012123:0.012796:0.007726:0.012219:0.005407:0.007735:0.017665:0.012123:0.006138:0.012758:0.007081:0.006138:0.012758:0.006138:0.003464:0.012065:0.007726:0.011353:0.012219:0.011353:0.006004:0.007081:0.017665:0.012758:0.003464:0.003464:0.006388
cell lung cancer even after failure of plati-:@0.084848:0.436410:0.475763:0.436410:0.475763:0.420654:0.084848:0.420654:0.012065:0.012123:0.003464:0.003464:0.007206:0.003464:0.011315:0.011353:0.012565:0.007206:0.012065:0.012758:0.011353:0.012065:0.012123:0.005407:0.007206:0.012123:0.010275:0.012123:0.011353:0.007206:0.012758:0.005657:0.006138:0.012123:0.005407:0.007206:0.005657:0.012758:0.003464:0.003464:0.011315:0.005328:0.012123:0.007206:0.012219:0.005657:0.007204:0.012738:0.003464:0.012758:0.006138:0.003464:0.006388
num-based:@0.084848:0.451928:0.188680:0.451928:0.188680:0.436172:0.084848:0.436172:0.011353:0.011315:0.017665:0.006004:0.012738:0.012758:0.007081:0.012123:0.012796
chemotherapy,:@0.213464:0.451928:0.354280:0.451928:0.354280:0.436172:0.213464:0.436172:0.012065:0.011353:0.012123:0.017665:0.012219:0.006138:0.011353:0.012123:0.005407:0.012758:0.012738:0.009929:0.004945
metastatic:@0.379064:0.451928:0.475776:0.451928:0.475776:0.436172:0.379064:0.436172:0.017665:0.012123:0.006138:0.012758:0.007081:0.006138:0.012758:0.006138:0.003464:0.012450
ovarian  cancer  after  failure  of  first-line  or :@0.084848:0.467446:0.481105:0.467446:0.481105:0.451690:0.084848:0.451690:0.012219:0.010275:0.012758:0.005407:0.003464:0.012758:0.011353:0.005330:0.004809:0.012065:0.012758:0.011353:0.012065:0.012123:0.005407:0.005330:0.004809:0.012758:0.005657:0.006138:0.012123:0.005407:0.005330:0.004807:0.005657:0.012758:0.003464:0.003464:0.011315:0.005328:0.012123:0.005330:0.004809:0.012219:0.005657:0.005330:0.004809:0.004493:0.004493:0.005407:0.007081:0.006138:0.006004:0.003464:0.003464:0.011353:0.012123:0.005330:0.004809:0.012219:0.005786:0.005330
subsequent therapy, androgen-independ-:@0.084848:0.482964:0.475773:0.482964:0.475773:0.467208:0.084848:0.467208:0.007081:0.011315:0.012738:0.007081:0.012123:0.012738:0.011315:0.012123:0.011353:0.006138:0.009948:0.006138:0.011353:0.012123:0.005407:0.012758:0.012738:0.009929:0.004945:0.009948:0.012758:0.011353:0.012796:0.005326:0.012219:0.012565:0.012123:0.011353:0.006004:0.003464:0.011353:0.012796:0.012123:0.012738:0.012123:0.011353:0.012796:0.006388
ent metastatic prostate cancer in combina-:@0.084848:0.498482:0.475813:0.498482:0.475813:0.482726:0.084848:0.482726:0.012123:0.011353:0.006138:0.004253:0.017665:0.012123:0.006138:0.012758:0.007081:0.006138:0.012758:0.006138:0.003464:0.012065:0.004253:0.012738:0.005328:0.012219:0.007081:0.006138:0.012758:0.006138:0.012123:0.004253:0.012065:0.012758:0.011353:0.012065:0.012123:0.005407:0.004253:0.003464:0.011353:0.004253:0.012065:0.012219:0.017665:0.012738:0.003464:0.011353:0.012758:0.006388
tion with prednisone/prednisolone, in com-:@0.084848:0.513999:0.475792:0.513999:0.475792:0.498243:0.084848:0.498243:0.006138:0.003464:0.012219:0.011353:0.007062:0.015606:0.003464:0.006138:0.011353:0.007062:0.012738:0.005328:0.012123:0.012796:0.011353:0.003464:0.007081:0.012219:0.011353:0.012123:0.008024:0.012738:0.005328:0.012123:0.012796:0.011353:0.003464:0.007081:0.012219:0.003464:0.012219:0.011353:0.012123:0.004945:0.007062:0.003464:0.011353:0.007062:0.012065:0.012219:0.017665:0.006388
bination with cisplatin and 5-fluorouracil for :@0.084848:0.529517:0.481083:0.529517:0.481083:0.513761:0.084848:0.513761:0.012738:0.003464:0.011353:0.012758:0.006138:0.003464:0.012219:0.011353:0.006598:0.015606:0.003464:0.006138:0.011353:0.006596:0.012065:0.003464:0.007081:0.012738:0.003464:0.012758:0.006138:0.003464:0.011353:0.006598:0.012758:0.011353:0.012796:0.006596:0.010275:0.006004:0.004474:0.004474:0.011315:0.012219:0.005328:0.012219:0.011315:0.005407:0.012758:0.012065:0.003464:0.003464:0.006596:0.005657:0.012219:0.005786:0.005330
induction treatment of patients with inoper-:@0.084848:0.545035:0.475794:0.545035:0.475794:0.529279:0.084848:0.529279:0.003464:0.011353:0.012796:0.011315:0.012065:0.006138:0.003464:0.012219:0.011353:0.005417:0.006138:0.005328:0.012123:0.012758:0.006138:0.017665:0.012123:0.011353:0.006138:0.005417:0.012219:0.005657:0.005417:0.012738:0.012758:0.006138:0.003464:0.012123:0.011353:0.006138:0.007081:0.005426:0.015606:0.003464:0.006138:0.011353:0.005417:0.003464:0.011353:0.012219:0.012738:0.012123:0.005407:0.006388
ative locally advanced squamous cell can-:@0.084848:0.560553:0.475719:0.560553:0.475719:0.544797:0.084848:0.544797:0.012758:0.006138:0.003464:0.010275:0.012123:0.005195:0.003464:0.012219:0.012065:0.012758:0.003464:0.003464:0.009929:0.005195:0.012758:0.012796:0.010275:0.012758:0.011353:0.012065:0.012123:0.012796:0.005195:0.007081:0.012738:0.011315:0.012758:0.017665:0.012219:0.011315:0.007081:0.005195:0.012065:0.012123:0.003464:0.003464:0.005195:0.012065:0.012758:0.011353:0.006388
cer of the head and neck.:@0.084848:0.576071:0.324610:0.576071:0.324610:0.560315:0.084848:0.560315:0.012065:0.012123:0.005407:0.005319:0.012219:0.005657:0.005321:0.006138:0.011353:0.012123:0.005319:0.011353:0.012123:0.012758:0.012796:0.005319:0.012758:0.011353:0.012796:0.005319:0.011353:0.012123:0.012065:0.009275:0.005330
4,13:@0.324197:0.570476:0.345277:0.570476:0.345277:0.561291:0.324197:0.561291:0.005991:0.002883:0.005991:0.006215
 New research :@0.345057:0.576095:0.481091:0.576095:0.481091:0.560340:0.345057:0.560340:0.005319:0.013855:0.012123:0.015606:0.005319:0.005328:0.012123:0.007081:0.012123:0.012758:0.005272:0.012065:0.011734:0.005330
has  shown  that  docetaxel  in  combination :@0.084842:0.591613:0.481091:0.591613:0.481091:0.575857:0.084842:0.575857:0.011353:0.012758:0.007081:0.005330:0.003181:0.007081:0.011353:0.012219:0.015606:0.011353:0.005330:0.003181:0.006138:0.011353:0.012758:0.006138:0.005330:0.003181:0.012796:0.012219:0.012065:0.012123:0.006138:0.012758:0.008852:0.012123:0.003464:0.005330:0.003183:0.003464:0.011353:0.005330:0.003181:0.012065:0.012219:0.017665:0.012738:0.003464:0.011353:0.012758:0.006138:0.003464:0.012219:0.011736:0.005330
with gemcitabine may be considered in the :@0.084842:0.607131:0.481116:0.607131:0.481116:0.591375:0.084842:0.591375:0.015606:0.003464:0.006138:0.011353:0.004426:0.012565:0.012123:0.017665:0.012065:0.003464:0.006138:0.012758:0.012738:0.003464:0.011353:0.012123:0.004426:0.017665:0.012758:0.009929:0.004426:0.012738:0.012123:0.004426:0.012065:0.012219:0.011353:0.007081:0.003464:0.012796:0.012123:0.005328:0.012123:0.012796:0.004426:0.003464:0.011353:0.004426:0.006138:0.011353:0.012506:0.005330
treatment of soft tissue sarcomas.  The :@0.084842:0.622649:0.481096:0.622651:0.481096:0.606895:0.084842:0.606893:0.006138:0.005328:0.012123:0.012758:0.006138:0.017665:0.012123:0.011353:0.006138:0.012700:0.012219:0.005657:0.012700:0.007081:0.012219:0.005657:0.006138:0.012700:0.006138:0.003464:0.007081:0.007081:0.011315:0.012123:0.012700:0.007081:0.012758:0.005270:0.012065:0.012219:0.017665:0.012758:0.007081:0.005330:0.017586:0.012700:0.007812:0.011353:0.012508:0.096022
111:@0.413415:0.617032:0.431611:0.617032:0.431611:0.607847:0.413415:0.607847:0.005991:0.005991:0.006215
combination with gemcitabine should be :@0.084856:0.638169:0.481133:0.638169:0.481133:0.622413:0.084856:0.622413:0.012065:0.012219:0.017665:0.012738:0.003464:0.011353:0.012758:0.006138:0.003464:0.012219:0.011353:0.009756:0.015606:0.003464:0.006138:0.011353:0.009756:0.012565:0.012123:0.017665:0.012065:0.003464:0.006138:0.012758:0.012738:0.003464:0.011353:0.012123:0.009756:0.007081:0.011353:0.012219:0.011315:0.003464:0.012796:0.009756:0.012738:0.012506:0.005330
used with caution. :@0.084856:0.653687:0.254592:0.653687:0.254592:0.637931:0.084856:0.637931:0.011315:0.007081:0.012123:0.012796:0.004945:0.015606:0.003464:0.006138:0.011353:0.004945:0.012065:0.012758:0.011315:0.006138:0.003464:0.012219:0.011353:0.005328:0.005330
Cabazitaxel  is  indicated for the treat-:@0.103041:0.669205:0.475768:0.669205:0.475768:0.653449:0.103041:0.653449:0.015644:0.013143:0.013123:0.013143:0.008178:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330:0.005207:0.003848:0.007466:0.005330:0.005209:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.010526:0.006042:0.012604:0.005792:0.010526:0.006523:0.011738:0.012508:0.010526:0.006523:0.005711:0.012508:0.013143:0.006523:0.006388
ment of patients with hormone-refractory :@0.084856:0.684723:0.481140:0.684723:0.481140:0.668967:0.084856:0.668967:0.018049:0.012508:0.011738:0.006523:0.006912:0.012604:0.006042:0.006927:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006927:0.015990:0.003848:0.006523:0.011738:0.006927:0.011738:0.012604:0.006317:0.018049:0.012604:0.011738:0.012508:0.006388:0.005711:0.012508:0.006042:0.005792:0.013143:0.012450:0.006523:0.012604:0.005792:0.010314:0.005330
metastatic prostate cancer  previously :@0.084856:0.700240:0.481106:0.700240:0.481106:0.684485:0.084856:0.684485:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.017761:0.013123:0.005715:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.017761:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.012421:0.013123:0.005715:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.003848:0.010314:0.005330
treated with a docetaxal-containing :@0.084856:0.715758:0.481110:0.715758:0.481110:0.700002:0.084856:0.700002:0.006523:0.005709:0.012508:0.013143:0.006523:0.012508:0.013181:0.021994:0.015990:0.003848:0.006523:0.011738:0.021994:0.013143:0.021994:0.013181:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.013143:0.003848:0.006388:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330
treatment regimen.:@0.084856:0.731276:0.266043:0.731276:0.266043:0.715520:0.084856:0.715520:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.005702:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.005330
37:@0.265602:0.725663:0.277785:0.725663:0.277785:0.716477:0.265602:0.716477:0.005968:0.006215
The main side effects of taxanes include::@0.084848:0.762319:0.463643:0.762319:0.463643:0.746563:0.084848:0.746563:0.008197:0.011738:0.012508:0.005330:0.018049:0.013143:0.003848:0.011738:0.005330:0.007466:0.003848:0.013181:0.012508:0.005330:0.012508:0.006088:0.006042:0.012508:0.012450:0.006523:0.007466:0.005330:0.012604:0.006042:0.005330:0.006523:0.013143:0.009236:0.013143:0.011738:0.012508:0.007466:0.005330:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.005330
4:@0.463627:0.756700:0.469842:0.756700:0.469842:0.747514:0.463627:0.747514:0.006215
n :@0.084848:0.775307:0.098177:0.775307:0.098177:0.766866:0.084848:0.766866:0.009762:0.003566
 :@0.115149:0.775307:0.118715:0.775307:0.118715:0.766866:0.115149:0.766866:0.003566
Nausea and vomiting :@0.115151:0.778426:0.321622:0.778426:0.321622:0.762670:0.115151:0.762670:0.014239:0.013143:0.011699:0.007466:0.012508:0.013143:0.005330:0.013143:0.011738:0.013181:0.005330:0.010660:0.012604:0.018049:0.003848:0.006523:0.003848:0.011738:0.012950:0.005330
n :@0.084848:0.791413:0.098177:0.791413:0.098177:0.782973:0.084848:0.782973:0.009762:0.003566
 :@0.115149:0.791413:0.118715:0.791413:0.118715:0.782973:0.115149:0.782973:0.003566
Hypotension :@0.115151:0.794532:0.236078:0.794532:0.236078:0.778776:0.115151:0.778776:0.013143:0.010314:0.013123:0.012604:0.006523:0.012508:0.011738:0.007466:0.003848:0.012604:0.011726:0.005330
n :@0.084848:0.807520:0.098177:0.807520:0.098177:0.799080:0.084848:0.799080:0.009762:0.003566
 :@0.115149:0.807520:0.118715:0.807520:0.118715:0.799080:0.115149:0.799080:0.003566
Arrhythmias :@0.115151:0.810639:0.229669:0.810639:0.229669:0.794883:0.115151:0.794883:0.014239:0.005792:0.006337:0.011738:0.010314:0.006523:0.011738:0.018049:0.003848:0.013143:0.007466:0.005330
n :@0.084848:0.823626:0.098177:0.823626:0.098177:0.815186:0.084848:0.815186:0.009762:0.003566
 :@0.115149:0.823626:0.118715:0.823626:0.118715:0.815186:0.115149:0.815186:0.003566
Hypersensitivity :@0.115151:0.826746:0.260104:0.826746:0.260104:0.810990:0.115151:0.810990:0.013143:0.010314:0.013123:0.012508:0.005792:0.007466:0.012508:0.011738:0.007466:0.003848:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.005330
n :@0.084848:0.839733:0.098177:0.839733:0.098177:0.831293:0.084848:0.831293:0.009762:0.003566
 :@0.115149:0.839733:0.118715:0.839733:0.118715:0.831293:0.115149:0.831293:0.003566
Myelosuppression with neutropaenia :@0.115151:0.842852:0.461226:0.842852:0.461226:0.827096:0.115151:0.827096:0.017684:0.010314:0.012508:0.003848:0.012604:0.007466:0.011699:0.013123:0.013123:0.005719:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.011738:0.012508:0.011682:0.006523:0.005709:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330
n :@0.084848:0.855840:0.098177:0.855840:0.098177:0.847399:0.084848:0.847399:0.009762:0.003566
 :@0.115149:0.855840:0.118715:0.855840:0.118715:0.847399:0.115149:0.847399:0.003566
Peripheral sensory neuropathy:@0.115151:0.858959:0.396479:0.858959:0.396479:0.843203:0.115151:0.843203:0.011392:0.012508:0.005792:0.003848:0.013123:0.011738:0.012508:0.005792:0.013143:0.003848:0.005330:0.007466:0.012508:0.011738:0.007466:0.012604:0.005792:0.010314:0.005330:0.011738:0.012508:0.011699:0.005700:0.012604:0.013123:0.013143:0.006523:0.011738:0.010314
n :@0.524242:0.073159:0.537570:0.073159:0.537570:0.064719:0.524242:0.064719:0.009762:0.003566
 :@0.554542:0.073159:0.558108:0.073159:0.558108:0.064719:0.554542:0.064719:0.003566
Neurotoxicity:@0.554545:0.076278:0.676653:0.076278:0.676653:0.060522:0.554545:0.060522:0.014239:0.012508:0.011699:0.005711:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314
n :@0.524242:0.089580:0.537570:0.089580:0.537570:0.081139:0.524242:0.081139:0.009762:0.003566
 :@0.554542:0.089580:0.558108:0.089580:0.558108:0.081139:0.554542:0.081139:0.003566
Fluid retention:@0.554545:0.092699:0.685484:0.092699:0.685484:0.076943:0.554545:0.076943:0.009333:0.003848:0.011699:0.003848:0.013181:0.005330:0.005709:0.012508:0.006523:0.012508:0.011738:0.006523:0.003848:0.012604:0.011738
EPOTHILONES:@0.524242:0.125423:0.660221:0.125423:0.660221:0.107608:0.524242:0.107608:0.011118:0.011973:0.017960:0.008980:0.014539:0.005987:0.009407:0.017960:0.015822:0.011118:0.011118
Ixabepilone is an epothilone B analogue :@0.524242:0.142402:0.920485:0.142402:0.920485:0.126646:0.524242:0.126646:0.004349:0.009236:0.013143:0.013123:0.012508:0.013123:0.003848:0.003848:0.012604:0.011738:0.012508:0.008197:0.003848:0.007466:0.008197:0.013143:0.011738:0.008197:0.012508:0.013123:0.012604:0.006523:0.011738:0.003848:0.003848:0.012604:0.011738:0.012508:0.008182:0.011045:0.008197:0.013143:0.011738:0.013143:0.003848:0.012604:0.012950:0.011699:0.012508:0.005330
from a relatively new class of antitumour :@0.524242:0.158238:0.920487:0.158238:0.920487:0.142482:0.524242:0.142482:0.006042:0.005711:0.012604:0.018049:0.007928:0.013143:0.007928:0.005713:0.012508:0.003848:0.013143:0.006523:0.003848:0.010660:0.012508:0.003848:0.010314:0.007928:0.011738:0.012508:0.015990:0.007928:0.012450:0.003848:0.013143:0.007466:0.007466:0.007939:0.012604:0.006042:0.007928:0.013143:0.011738:0.006523:0.003848:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005330
agents  and  a novel microtubule inhibi-:@0.524242:0.174073:0.915163:0.174073:0.915163:0.158317:0.524242:0.158317:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330:0.006148:0.013143:0.011738:0.013181:0.005330:0.006158:0.013143:0.011488:0.011738:0.012604:0.010660:0.012508:0.003848:0.011488:0.018049:0.003848:0.012450:0.005717:0.012604:0.006523:0.011699:0.013123:0.011699:0.003848:0.012508:0.011488:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006388
tor.:@0.524242:0.189763:0.553071:0.189763:0.553071:0.174007:0.524242:0.174007:0.006523:0.012604:0.004372:0.005330
4,38:@0.553068:0.184135:0.574820:0.184135:0.574820:0.174950:0.553068:0.174950:0.006215:0.003107:0.006215:0.006215
 The epothilones were developed to :@0.574825:0.189754:0.920511:0.189754:0.920511:0.173998:0.574825:0.173998:0.005888:0.008197:0.011738:0.012508:0.005888:0.012508:0.013123:0.012604:0.006523:0.011738:0.003848:0.003848:0.012604:0.011738:0.012508:0.007466:0.005888:0.015990:0.012508:0.005711:0.012508:0.005888:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.012508:0.013181:0.005888:0.006523:0.012604:0.005330
overcome  tumour-resistant mechanisms. :@0.524237:0.205444:0.920490:0.205444:0.920490:0.189688:0.524237:0.189688:0.012604:0.010660:0.012508:0.005653:0.012450:0.012604:0.018049:0.012508:0.005330:0.006873:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.006388:0.005709:0.012508:0.007466:0.003848:0.007466:0.006523:0.013143:0.011738:0.006523:0.012219:0.018049:0.012508:0.012450:0.011738:0.013143:0.011738:0.003848:0.007466:0.018049:0.007466:0.005330:0.005330
Ixabepilone has activity in drug-resistant :@0.524237:0.220829:0.920486:0.220829:0.920486:0.205074:0.524237:0.205074:0.004349:0.009236:0.013143:0.013123:0.012508:0.013123:0.003848:0.003848:0.012604:0.011738:0.012508:0.010179:0.011738:0.013143:0.007466:0.010179:0.013143:0.012450:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.010179:0.003848:0.011738:0.010179:0.013181:0.005792:0.011699:0.012950:0.006388:0.005705:0.012508:0.007466:0.003848:0.007466:0.006523:0.013143:0.011738:0.006523:0.005330
tumours  that  overexpress tubulin muta-:@0.524237:0.236215:0.915160:0.236215:0.915160:0.220459:0.524237:0.220459:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330:0.007503:0.006523:0.011738:0.013143:0.006523:0.005330:0.007508:0.012604:0.010660:0.012508:0.005709:0.012508:0.009236:0.013123:0.005713:0.012508:0.007466:0.007466:0.012854:0.006523:0.011699:0.013123:0.011699:0.003848:0.003848:0.011738:0.012854:0.018049:0.011699:0.006523:0.013143:0.006388
tions.:@0.524237:0.251601:0.571746:0.251601:0.571746:0.235845:0.524237:0.235845:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330
4,38  :@0.571746:0.245997:0.602238:0.245997:0.602238:0.236811:0.571746:0.236811:0.006215:0.003107:0.006215:0.006215:0.005632:0.003107
Ixabepilone binds to the  tubulin :@0.604763:0.251616:0.920483:0.251616:0.920483:0.235860:0.604763:0.235860:0.004349:0.009236:0.013143:0.013123:0.012508:0.013123:0.003848:0.003848:0.012604:0.011738:0.012508:0.009660:0.013123:0.003848:0.011738:0.013181:0.007466:0.009660:0.006523:0.012604:0.009660:0.006523:0.011738:0.012508:0.005330:0.004320:0.006523:0.011699:0.013123:0.011699:0.003848:0.003848:0.011738:0.005330
during mitosis and thereby stabilises  the :@0.524234:0.267002:0.920464:0.267002:0.920464:0.251246:0.524234:0.251246:0.013181:0.011699:0.005792:0.003848:0.011738:0.012950:0.010275:0.018049:0.003848:0.006523:0.012604:0.007466:0.003848:0.007466:0.010275:0.013143:0.011738:0.013181:0.010275:0.006523:0.011738:0.012508:0.005705:0.012508:0.013123:0.010314:0.010275:0.007466:0.006523:0.013143:0.013123:0.003848:0.003848:0.003848:0.007466:0.012508:0.007466:0.005330:0.004965:0.006523:0.011738:0.012508:0.005330
microtubules, halting the cell cycle.  :@0.524234:0.282387:0.866067:0.282400:0.866067:0.266644:0.524234:0.266631:0.018049:0.003848:0.012450:0.005715:0.012604:0.006523:0.011699:0.013123:0.011699:0.003848:0.012508:0.007466:0.005330:0.005330:0.011738:0.013143:0.003848:0.006523:0.003848:0.011738:0.012950:0.005330:0.006523:0.011738:0.012508:0.005330:0.012450:0.012508:0.003848:0.003848:0.005330:0.012450:0.010314:0.012450:0.003848:0.012508:0.005330:0.006207:0.205962
4:@0.854520:0.276781:0.860734:0.276781:0.860734:0.267595:0.854520:0.267595:0.006215
Ixabepilone is  indicated for the treat-:@0.542429:0.297786:0.915145:0.297786:0.915145:0.282030:0.542429:0.282030:0.004349:0.009236:0.013143:0.013123:0.012508:0.013123:0.003848:0.003848:0.012604:0.011738:0.012508:0.010987:0.003848:0.007466:0.005330:0.005671:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.010987:0.006042:0.012604:0.005792:0.010987:0.006523:0.011738:0.012508:0.010987:0.006523:0.005711:0.012508:0.013143:0.006523:0.006388
ment  of locally advanced or  metastatic :@0.524245:0.313171:0.920481:0.313171:0.920481:0.297415:0.524245:0.297415:0.018049:0.012508:0.011738:0.006523:0.005330:0.003625:0.012604:0.006042:0.008967:0.003848:0.012604:0.012450:0.013143:0.003848:0.003848:0.010314:0.008967:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.008967:0.012604:0.005792:0.005330:0.003625:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330
breast cancer after cytotoxic chemother-:@0.524245:0.328557:0.915154:0.328557:0.915154:0.312801:0.524245:0.312801:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005888:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005877:0.013143:0.006042:0.006523:0.012508:0.005792:0.005877:0.012450:0.010314:0.006523:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.005888:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005757:0.006388
apy has failed;  as combination  therapy :@0.524245:0.343942:0.920496:0.343942:0.920496:0.328186:0.524245:0.328186:0.013143:0.013123:0.010314:0.010141:0.011738:0.013143:0.007466:0.010141:0.006042:0.013143:0.003848:0.003848:0.012508:0.013181:0.005330:0.005330:0.004797:0.013143:0.007466:0.010141:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.004797:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
with  capecitabine  in patients who  have :@0.524245:0.359328:0.920490:0.359328:0.920490:0.343572:0.524245:0.343572:0.015990:0.003848:0.006523:0.011738:0.005330:0.003781:0.012450:0.013143:0.013123:0.012508:0.012450:0.003848:0.006523:0.013143:0.013123:0.003848:0.011738:0.012508:0.005330:0.003781:0.003848:0.011738:0.009121:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.009121:0.015990:0.011738:0.012604:0.005330:0.003777:0.011738:0.013143:0.010660:0.012508:0.005330
failed prior therapy with a taxane and an :@0.524245:0.374713:0.920486:0.374713:0.920486:0.358957:0.524245:0.358957:0.006042:0.013143:0.003848:0.003848:0.012508:0.013181:0.006235:0.013123:0.005792:0.003848:0.012604:0.005792:0.006217:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.006219:0.015990:0.003848:0.006523:0.011738:0.006225:0.013143:0.006225:0.006523:0.013143:0.009236:0.013143:0.011738:0.012508:0.006221:0.013143:0.011738:0.013181:0.006225:0.013143:0.011738:0.005330
anthracycline or  where further  anthracy-:@0.524245:0.390099:0.915172:0.390099:0.915172:0.374343:0.524245:0.374343:0.013143:0.011738:0.006523:0.011738:0.005792:0.013143:0.012450:0.010314:0.012450:0.003848:0.003848:0.011738:0.012508:0.008390:0.012604:0.005792:0.005330:0.003048:0.015990:0.011738:0.012508:0.005709:0.012508:0.008390:0.006042:0.011699:0.005792:0.006523:0.011738:0.012494:0.005792:0.005330:0.003050:0.013143:0.011738:0.006523:0.011738:0.005792:0.013143:0.012450:0.010314:0.006388
cline therapy is not indicated; as mono-:@0.524245:0.405484:0.915154:0.405484:0.915154:0.389728:0.524245:0.389728:0.012450:0.003848:0.003848:0.011738:0.012508:0.008909:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.008909:0.003848:0.007466:0.008909:0.011738:0.012604:0.006523:0.008909:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005330:0.008909:0.013143:0.007466:0.008909:0.018049:0.012604:0.011738:0.012604:0.006388
therapy for patients in whom prior therapy :@0.524245:0.420870:0.920494:0.420870:0.920494:0.405114:0.524245:0.405114:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005032:0.006042:0.012604:0.005792:0.005028:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005042:0.003848:0.011738:0.005042:0.015990:0.011738:0.012604:0.018049:0.005030:0.013123:0.005792:0.003848:0.012604:0.005792:0.005028:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
with a taxane or anthracycline has failed.  :@0.524245:0.436255:0.920481:0.436320:0.920481:0.420564:0.524245:0.420499:0.015990:0.003848:0.006523:0.011738:0.003848:0.013143:0.003848:0.006523:0.013143:0.009236:0.013143:0.011738:0.012508:0.003848:0.012604:0.005792:0.003848:0.013143:0.011738:0.006523:0.011738:0.005792:0.013143:0.012450:0.010314:0.012450:0.003848:0.003848:0.011738:0.012508:0.003848:0.011738:0.013143:0.007466:0.003848:0.006042:0.013143:0.003848:0.003848:0.012508:0.013181:0.005330:0.012408:-0.072335
13:@0.902716:0.430701:0.915146:0.430701:0.915146:0.421515:0.902716:0.421515:0.006215:0.006215
Ixabepilone’s main side effects include: :@0.524241:0.467104:0.897128:0.467104:0.897128:0.451348:0.524241:0.451348:0.004349:0.009236:0.013143:0.013123:0.012508:0.013123:0.003848:0.003848:0.012604:0.011738:0.012508:0.006754:0.007466:0.005330:0.018049:0.013143:0.003848:0.011738:0.005330:0.007466:0.003848:0.013181:0.012508:0.005330:0.012508:0.006108:0.006042:0.012508:0.012450:0.006523:0.007466:0.005330:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.005330:0.005330
4:@0.897120:0.461485:0.903334:0.461485:0.903334:0.452299:0.897120:0.452299:0.006215
n :@0.524242:0.479965:0.537570:0.479965:0.537570:0.471524:0.524242:0.471524:0.009762:0.003566
 :@0.554542:0.479965:0.558108:0.479965:0.558108:0.471524:0.554542:0.471524:0.003566
Myelosuppression :@0.554545:0.483084:0.723593:0.483084:0.723593:0.467328:0.554545:0.467328:0.017684:0.010314:0.012508:0.003848:0.012604:0.007466:0.011699:0.013123:0.013123:0.005719:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330
n :@0.524242:0.495945:0.537570:0.495945:0.537570:0.487504:0.524242:0.487504:0.009762:0.003566
 :@0.554542:0.495945:0.558108:0.495945:0.558108:0.487504:0.554542:0.487504:0.003566
Hypersensitivity reactions:@0.554545:0.499064:0.785488:0.499064:0.785488:0.483308:0.554545:0.483308:0.013143:0.010314:0.013123:0.012508:0.005792:0.007466:0.012508:0.011738:0.007466:0.003848:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.005330:0.005711:0.012508:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466
n :@0.524242:0.511924:0.537570:0.511924:0.537570:0.503484:0.524242:0.503484:0.009762:0.003566
 :@0.554542:0.511924:0.558108:0.511924:0.558108:0.503484:0.554542:0.503484:0.003566
Neurotoxicity in the form of peripheral :@0.554545:0.515044:0.912059:0.515044:0.912059:0.499288:0.554545:0.499288:0.014239:0.012508:0.011699:0.005711:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330:0.003848:0.011738:0.005330:0.006523:0.011738:0.012508:0.005330:0.006042:0.012604:0.006306:0.018049:0.005330:0.012604:0.006042:0.005330:0.013123:0.012508:0.005792:0.003848:0.013123:0.011738:0.012508:0.005792:0.013143:0.003848:0.005330
sensory neuropathy:@0.554545:0.530429:0.736851:0.530429:0.736851:0.514673:0.554545:0.514673:0.007466:0.012508:0.011738:0.007466:0.012604:0.005792:0.010314:0.005330:0.011738:0.012508:0.011699:0.005700:0.012604:0.013123:0.013143:0.006523:0.011738:0.010314
Contra-indications, special  precautions :@0.542422:0.545815:0.920489:0.545815:0.920489:0.530059:0.542422:0.530059:0.015644:0.012604:0.011738:0.006523:0.005792:0.013143:0.006388:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.008986:0.007466:0.013123:0.012508:0.012450:0.003848:0.013143:0.003848:0.005330:0.003670:0.013123:0.005713:0.012508:0.012450:0.013143:0.011699:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330
and drug interactions: See :@0.524238:0.561200:0.778594:0.561200:0.778594:0.545444:0.524238:0.545444:0.013143:0.011738:0.013181:0.006413:0.013181:0.005792:0.011699:0.012950:0.006410:0.003848:0.011738:0.006523:0.012508:0.005792:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.006410:0.009583:0.012508:0.012508:0.005330
MIMS Monthly, :@0.779662:0.561200:0.920478:0.561200:0.920478:0.545444:0.779662:0.545444:0.017684:0.004349:0.017684:0.009583:0.006408:0.017684:0.012604:0.011738:0.006523:0.011738:0.003848:0.010314:0.005330:0.005330
MDR:@0.524238:0.576586:0.567918:0.576586:0.567918:0.560830:0.524238:0.560830:0.017684:0.014316:0.011680
 or manufacturer’s product literature.:@0.567918:0.576586:0.913046:0.576586:0.913046:0.560830:0.567918:0.560830:0.005330:0.012604:0.005792:0.005330:0.018049:0.013143:0.011738:0.011699:0.006042:0.013143:0.012450:0.006523:0.011699:0.005694:0.012508:0.005792:0.006754:0.007466:0.005330:0.013123:0.005711:0.012604:0.013181:0.011699:0.012450:0.006523:0.005330:0.003848:0.003848:0.006523:0.012508:0.005792:0.013143:0.006523:0.011699:0.005698:0.012508:0.005330
OTHERS:@0.524242:0.608454:0.600356:0.608454:0.600356:0.590639:0.524242:0.590639:0.017960:0.008980:0.014539:0.011118:0.012401:0.011118
Eribulin inhibits the growth phase of micro-:@0.524242:0.624992:0.915159:0.624992:0.915159:0.609236:0.524242:0.609236:0.010314:0.005792:0.003848:0.013123:0.011699:0.003848:0.003848:0.011738:0.005446:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.007466:0.005446:0.006523:0.011738:0.012508:0.005426:0.012950:0.005709:0.012604:0.015990:0.006523:0.011738:0.005426:0.013123:0.011738:0.013143:0.007466:0.012508:0.005436:0.012604:0.006042:0.005428:0.018049:0.003848:0.012450:0.005717:0.012604:0.006388
tubules without affecting the shortening :@0.524242:0.640378:0.920520:0.640378:0.920520:0.624622:0.524242:0.624622:0.006523:0.011699:0.013123:0.011699:0.003848:0.012508:0.007466:0.010545:0.015990:0.003848:0.006523:0.011738:0.012604:0.011699:0.006523:0.010545:0.013143:0.006100:0.006042:0.012508:0.012450:0.006523:0.003848:0.011738:0.012950:0.010545:0.006523:0.011738:0.012508:0.010545:0.007466:0.011738:0.012604:0.005792:0.006523:0.012508:0.011738:0.003848:0.011738:0.012950:0.005330
phase and  sequesters  tubulin into  non-:@0.524242:0.655763:0.915172:0.655763:0.915172:0.640007:0.524242:0.640007:0.013123:0.011738:0.013143:0.007466:0.012508:0.011642:0.013143:0.011738:0.013181:0.005330:0.006302:0.007466:0.012508:0.013123:0.011699:0.012508:0.007466:0.006523:0.012508:0.005792:0.007466:0.005330:0.006300:0.006523:0.011699:0.013123:0.011699:0.003848:0.003848:0.011738:0.011642:0.003848:0.011738:0.006523:0.012604:0.005330:0.006296:0.011738:0.012604:0.011738:0.006388
productive aggregates.  Eribulin exerts its :@0.524242:0.671149:0.920476:0.671168:0.920476:0.655412:0.524242:0.655393:0.013123:0.005715:0.012604:0.013181:0.011699:0.012450:0.006523:0.003848:0.010660:0.012508:0.004676:0.013143:0.012950:0.012950:0.005713:0.012508:0.012950:0.013143:0.006523:0.012508:0.007466:0.005330:0.018635:0.004676:0.010314:0.005792:0.003848:0.013123:0.011699:0.003848:0.003848:0.011738:0.004676:0.012508:0.009236:0.012508:0.005792:0.006523:0.007466:0.004664:0.003848:0.006523:0.007466:-0.413928
124:@0.746396:0.665549:0.765041:0.665549:0.765041:0.656364:0.746396:0.656364:0.006215:0.006215:0.006215
effects via a tubulin-based antimitotic :@0.524248:0.686554:0.920465:0.686554:0.920465:0.670798:0.524248:0.670798:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.014778:0.010660:0.003848:0.013143:0.014778:0.013143:0.014778:0.006523:0.011699:0.013123:0.011699:0.003848:0.003848:0.011738:0.006388:0.013123:0.013143:0.007466:0.012508:0.013181:0.014778:0.013143:0.011738:0.006523:0.003848:0.018049:0.003848:0.006523:0.012604:0.006523:0.003848:0.012450:0.005330
mechanism, leading to G2/M cell-cycle :@0.524248:0.701939:0.920488:0.701939:0.920488:0.686183:0.524248:0.686183:0.018049:0.012508:0.012450:0.011738:0.013143:0.011738:0.003848:0.007466:0.018049:0.005330:0.010526:0.003848:0.012508:0.013143:0.013181:0.003848:0.011738:0.012950:0.010526:0.006523:0.012604:0.010526:0.016779:0.010660:0.008409:0.017684:0.010526:0.012450:0.012508:0.003848:0.003848:0.006388:0.012450:0.010314:0.012450:0.003848:0.012508:0.005330
block, disruption of mitotic spindles, and :@0.524248:0.717325:0.920507:0.717325:0.920507:0.701569:0.524248:0.701569:0.013123:0.003848:0.012604:0.012450:0.009660:0.005330:0.009005:0.013181:0.003848:0.007466:0.005792:0.011699:0.013123:0.006523:0.003848:0.012604:0.011738:0.009005:0.012604:0.006042:0.009005:0.018049:0.003848:0.006523:0.012604:0.006523:0.003848:0.012450:0.009005:0.007466:0.013123:0.003848:0.011738:0.013181:0.003848:0.012508:0.007466:0.005330:0.009005:0.013143:0.011738:0.013181:0.005330
ultimately, apoptotic cell death after pro-:@0.524248:0.732710:0.915150:0.732710:0.915150:0.716954:0.524248:0.716954:0.011699:0.003848:0.006523:0.003848:0.018049:0.013143:0.006523:0.012508:0.003848:0.010314:0.005330:0.005946:0.013143:0.013123:0.012604:0.013123:0.006523:0.012604:0.006523:0.003848:0.012450:0.005946:0.012450:0.012508:0.003848:0.003848:0.005957:0.013181:0.012508:0.013143:0.006523:0.011738:0.005946:0.013143:0.006042:0.006523:0.012508:0.005792:0.005946:0.013123:0.005715:0.012604:0.006388
longed mitotic blockage.:@0.524248:0.748096:0.761199:0.748096:0.761199:0.732340:0.524248:0.732340:0.003848:0.012604:0.011738:0.012950:0.012508:0.013181:0.005330:0.018049:0.003848:0.006523:0.012604:0.006523:0.003848:0.012450:0.005330:0.013123:0.003848:0.012604:0.012450:0.009660:0.013143:0.012950:0.012508:0.005330
Eribulin is indicated as monotherapy in :@0.542432:0.763931:0.920457:0.763931:0.920457:0.748175:0.542432:0.748175:0.010314:0.005792:0.003848:0.013123:0.011699:0.003848:0.003848:0.011738:0.008486:0.003848:0.007466:0.008486:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.008486:0.013143:0.007466:0.008486:0.018049:0.012604:0.011738:0.012592:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.008486:0.003848:0.011738:0.005330
patients with  locally advanced or  meta-:@0.524248:0.779766:0.915167:0.779766:0.915167:0.764010:0.524248:0.764010:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008582:0.015990:0.003848:0.006523:0.011738:0.005330:0.003242:0.003848:0.012604:0.012450:0.013143:0.003848:0.003848:0.010314:0.008582:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.008582:0.012604:0.005792:0.005330:0.003233:0.018049:0.012508:0.006523:0.013143:0.006388
static breast cancer who have progressed :@0.524248:0.795602:0.920486:0.795602:0.920486:0.779846:0.524248:0.779846:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.004560:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.004560:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.004549:0.015990:0.011738:0.012604:0.004560:0.011738:0.013143:0.010660:0.012508:0.004560:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.005330
after at least two chemotherapy regimens :@0.524248:0.811437:0.920488:0.811437:0.920488:0.795681:0.524248:0.795681:0.013143:0.006042:0.006523:0.012508:0.005792:0.004676:0.013143:0.006523:0.004676:0.003848:0.012508:0.013143:0.007466:0.006523:0.004676:0.006523:0.015990:0.012604:0.004676:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013125:0.013123:0.010314:0.004676:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.005330
for advanced disease.  Prior therapy had :@0.524248:0.827272:0.920486:0.827293:0.920486:0.811537:0.524248:0.811516:0.006042:0.012604:0.005792:0.005584:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.005600:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.012435:0.005600:0.011392:0.005792:0.003848:0.012604:0.005792:0.005580:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005590:0.011738:0.013143:0.013181:-0.641028
13:@0.735322:0.821674:0.747752:0.821674:0.747752:0.812488:0.735322:0.812488:0.006215:0.006215
to include an anthracycline and a taxane :@0.524237:0.843128:0.920492:0.843128:0.920492:0.827372:0.524237:0.827372:0.006523:0.012604:0.005145:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.005157:0.013143:0.011738:0.005157:0.013143:0.011738:0.006523:0.011738:0.005792:0.013143:0.012450:0.010314:0.012450:0.003848:0.003848:0.011738:0.012508:0.005145:0.013143:0.011738:0.013181:0.005157:0.013143:0.005157:0.006523:0.013143:0.009236:0.013143:0.011738:0.012508:0.005330
unless the patient is not suitable.:@0.524237:0.858963:0.823456:0.858963:0.823456:0.843207:0.524237:0.843207:0.011699:0.011738:0.003848:0.012508:0.007466:0.007466:0.005330:0.006523:0.011738:0.012508:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330:0.003848:0.007466:0.005330:0.011738:0.012604:0.006523:0.005330:0.007466:0.011699:0.003848:0.006523:0.013143:0.013123:0.003848:0.012508:0.005330
M-Phase-Specific Agents:@0.631840:0.038601:0.914556:0.038601:0.914556:0.019343:0.631840:0.019343:0.021613:0.007808:0.013923:0.014346:0.016063:0.009125:0.015287:0.007808:0.011712:0.016040:0.015287:0.015216:0.004704:0.007385:0.004704:0.015216:0.006515:0.017404:0.015828:0.015287:0.014346:0.007973:0.009125